Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PPI in EMEA’s centralized switch

This article was originally published in The Tan Sheet

Executive Summary

The European Medicines Agency's Committee for Medicinal Products for Human Use recommends selling the proton pump inhibitor Pantozol Control (pantoprazole 20 mg) OTC, according to a Feb. 19 release. The Nycomed GmbH product is the first PPI recommended for OTC status across Europe and is the second product recommended for OTC sale through Europe's centralized switch process. The first centrally switched nonprescription product in Europe is GlaxoSmithKline's weight-loss drug alli (1"The Tan Sheet" Oct. 27, 2008, p. 3)

You may also be interested in...



Nycomed Prepares To Launch First Nonprescription PPI With EU-Wide Approval

Nycomed is gearing up to launchPantozol Control (pantoprazole 20 mg) later this year when the firm expects an approval for European Union nonprescription marketing authorization

Alli Pioneers EU Centralized Process For Nonprescription Switch

The European Medicines Agency's clearance of GlaxoSmithKline's weight-loss drug alli for nonprescription status across the European Union marks the first success for a centralized Rx-to-OTC switch process

Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.

Topics

UsernamePublicRestriction

Register

PS102644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel